Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
262.7 EUR | +1.04% | -0.04% | -9.88% |
04:19pm | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
04:00pm | Transcript : Genmab A/S - Special Call |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 28.56 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.88% | 18.16B | - | ||
+14.72% | 118B | B+ | ||
+12.95% | 106B | B+ | ||
-3.09% | 24.28B | B+ | ||
+1.14% | 21.96B | B | ||
-42.28% | 16.37B | A- | ||
-17.19% | 15.56B | B | ||
+4.43% | 13.63B | C+ | ||
+28.37% | 12.27B | C+ | ||
+85.14% | 8.87B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock
- Ratings Genmab A/S